Publication | Open Access

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient

Durable Tumor ResponseCancer ImmunosurveillanceMedicineMelanomaImmunologyImmunoeditingImmune Checkpoint InhibitorDermatologyImmunotherapyOncologyTumor MicroenvironmentBroad T-cell Response